Significance of alternative splicing in drug resistance of chronic myeloid leukemia
10.3969/j.issn.1000-8179.2019.16.681
- VernacularTitle:选择性剪接在慢性髓系白血病耐药中的意义*
- Author:
Tingyu QIN
1
;
Jing LIU
;
Xiaozhong WANG
Author Information
1. 南昌大学第二附属医院检验科
- Keywords:
chronic myeloid leukemia (CML);
drug resistance;
alternative splicing (AS)
- From:
Chinese Journal of Clinical Oncology
2019;46(16):861-864
- CountryChina
- Language:Chinese
-
Abstract:
Alternative splicing (AS) is a process by which the transcriptome diversity, and thereby the proteome diversity, is augment-ed by splicing or joining together different parts of the pre-mRNA in eukaryotic cells . AS at different splice sites is regulated by multi-ple cis-acting elements and trans-acting factors. Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease in which there is a translocation between the long arms of chromosome 9 and chromosome 22, represented as t(9;22) (q34;q11). This translocation results in the formation of a BCR-ABL fusion gene. Hence it is not surprising that resistance to tyrosine kinase inhibitors, which inhibit BCR-ABL activity, has become a critical problem in the clinical treatment of CML. Using second generation high-throughput sequencing technology, it has been found that AS abnormalities are closely related to the occurrence, progression, drug resistance, and immune escape of CML. This paper reviews the research related to AS and CML resistance and investigates the potential causes of CML resis-tance. Drug resistance mechanisms and potential therapeutic targets are also reviewed.
